[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 620,144
  • Shares Outstanding, K 266,156
  • Annual Sales, $ 75,390 K
  • Annual Income, $ -287,530 K
  • EBIT $ -265 M
  • EBITDA $ -255 M
  • 60-Month Beta 2.07
  • Price/Sales 7.31
  • Price/Cash Flow N/A
  • Price/Book 5.06

Options Overview Details

View History
  • Implied Volatility 80.37% (-40.84%)
  • Historical Volatility 91.58%
  • IV Percentile 1%
  • IV Rank 0.10%
  • IV High 697.19% on 11/10/25
  • IV Low 79.75% on 05/19/26
  • Expected Move (DTE 9) 0.40 (18.76%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 211
  • Volume Avg (30-Day) 290
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 9,463
  • Open Int (30-Day) 9,471
  • Expected Range 1.73 to 2.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.22
  • Number of Estimates 2
  • High Estimate $-0.21
  • Low Estimate $-0.24
  • Prior Year $-0.30
  • Growth Rate Est. (year over year) +26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.38 +53.62%
on 07/21/26
2.43 -12.76%
on 08/11/26
+0.51 (+31.68%)
since 07/10/26
3-Month
1.38 +53.62%
on 07/21/26
2.43 -12.76%
on 08/11/26
+0.52 (+32.50%)
since 05/12/26
52-Week
1.17 +80.43%
on 03/27/26
2.43 -12.76%
on 08/11/26
-0.04 (-1.62%)
since 08/12/25

Most Recent Stories

More News
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-year FY 2026 net product revenue guidance increased to...

AUTL : 2.13 (-8.58%)
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 2.13 (-8.58%)
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors

Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million,...

AUTL : 2.13 (-8.58%)
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 2.13 (-8.58%)
Autolus Therapeutics to Participate in Upcoming Investor Conference

LONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 2.13 (-8.58%)
Autolus Therapeutics Receives Prix Galien UK Award

LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 2.13 (-8.58%)
Autolus Therapeutics to Participate in Upcoming Investor Conferences

LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 2.13 (-8.58%)
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 2.13 (-8.58%)
Autolus Therapeutics Q1 Earnings Call Highlights

Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue...

AUTL : 2.13 (-8.58%)
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive...

AUTL : 2.13 (-8.58%)

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London,...

See More

Key Turning Points

3rd Resistance Point 2.91
2nd Resistance Point 2.67
1st Resistance Point 2.50
Last Price 2.13
1st Support Level 2.09
2nd Support Level 1.85
3rd Support Level 1.68

See More

52-Week High 2.43
Last Price 2.13
Fibonacci 61.8% 1.95
Fibonacci 50% 1.80
Fibonacci 38.2% 1.65
52-Week Low 1.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.